Compare TONX & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TONX | BWAY |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.4M | 280.7M |
| IPO Year | N/A | 2019 |
| Metric | TONX | BWAY |
|---|---|---|
| Price | $3.06 | $17.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.50 |
| AVG Volume (30 Days) | ★ 715.7K | 71.4K |
| Earning Date | 11-12-2025 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 213.09 |
| EPS | ★ 7.29 | 0.13 |
| Revenue | $7,760,000.00 | ★ $49,094,000.00 |
| Revenue This Year | $526.82 | $330.76 |
| Revenue Next Year | $45.45 | $22.24 |
| P/E Ratio | ★ $0.42 | $53.44 |
| Revenue Growth | ★ 3760.70 | 27.08 |
| 52 Week Low | $2.73 | $7.84 |
| 52 Week High | $29.77 | $17.92 |
| Indicator | TONX | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 60.44 |
| Support Level | N/A | $16.67 |
| Resistance Level | N/A | $17.75 |
| Average True Range (ATR) | 0.00 | 0.83 |
| MACD | 0.00 | 0.22 |
| Stochastic Oscillator | 0.00 | 86.93 |
TON Strategy Co is a leader in interactive video-based sales applications, transforms how businesses attract and engage customers. The company's Software-as-a-Service platform, based on its proprietary interactive video technology, comprises a suite of easy-to-use, subscription-based sales enablement software products. The segments of the company are MARKET.live and Go Fund Yourself, and it derives maximum revenue from MARKET.live segment.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.